dremisan
msf marketing service gmbh - simeticon - granulat - simeticon 3.g
dremisan granulat
msf marketing service gmbh - simeticon - granulat - simeticon 3.g
pegasys 135 mcg/0,5 ml injektionslösung in einer fertigspritze
cps cito pharma services gmbh - peginterferonum alfa-2a - injektionslösung in einer fertigspritze - peginterferonum alfa-2a 135 µg, natrii chloridum, alcohol benzylicus 5 mg, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, natrii acetas trihydricus aut acidum aceticum ad ph, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - chronische hepatitis b, chronische hepatitis c - biotechnologika
pegasys 180 mcg/0,5 ml injektionslösung in einer fertigspritze
cps cito pharma services gmbh - peginterferonum alfa-2a - injektionslösung in einer fertigspritze - peginterferonum alfa-2a 180 µg, natrii chloridum, alcohol benzylicus 5 mg, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, natrii acetas trihydricus aut acidum aceticum ad ph, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - chronische hepatitis b, chronische hepatitis c - biotechnologika
irinotecan onkovis 20 mg/ml konzentrat zur herstellung einer infusionslösung
onkovis gmbh (8111905) - irinotecanhydrochlorid 3 h<2>o - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; irinotecanhydrochlorid 3 h<2>o (28859) 20 milligramm
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicinhydrochlorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastische mittel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
pirfenidon beta 267 mg filmtabletten
betapharm arzneimittel gmbh (3364323) - filmtablette - 267 mg
pirfenidon beta 534 mg filmtabletten
betapharm arzneimittel gmbh (3364323) - filmtablette - 534 mg
pirfenidon beta 801 mg filmtabletten
betapharm arzneimittel gmbh (3364323) - filmtablette - 801 mg
pirfenidon glenmark 267 mg filmtabletten
glenmark arzneimittel gmbh (8139306) - filmtablette - 267 mg